cancer treatment based combination systemic chemotherapy radiotherapy new methods therapy based biological priniciples introduced decade monoclonal antibody rituximab launched years ago NUMBER antibody cd20 antigen expressed b cell lymphocytes majority lymphoid malignancies revolutionized lymphoma therapeutic strategy dramatically improved outcome diffuse large lymphomas patients combination rituximab chemotherapy line therapy time improved survival follicular lymphoma patients previously considered incurable rituximab inevitable therapeutic regimens lymphomas chronic lymphocytic leukaemia diseases important milestones therapeutic results rituximab approved monoclonal antibodies alemtuzumab ibritumomab tiuxetan 90y reviewed paper short compendium new antibodies given cost effectiveness new therapy discussed references NUMBER b cell immuno chemotherapy b cell b cell non malignant